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G-protein-coupled receptors (GPCRs) comprise a large family of cell-surface receptors, which have re-
cently emerged as key players in tumorigenesis, angiogenesis and metastasis. In this review, we dis-
cussed our current understanding of the many roles played by GPCRs in general, and particularly An-
giotensin II type I receptor (AGTR1), a member of the seven-transmembrane-spanning G-protein coupled
receptor superfamily, and its signiﬁcance in breast cancer progression and metastasis. We have also
discussed different strategies for targeting AGTR1, and its ligand Angiotension II (Ang II), which might
unravel unique opportunities for breast cancer prevention and treatment. For example, AGTR1 blockers
(ARBs) which are already in clinical use for treating hypertension, merit further investigation as a
therapeutic strategy for AGTR1-positive cancer patients and may have the potential to prevent Ang II-
AGTR1 signalling mediated cancer pathogenesis and metastases.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
G-protein-coupled receptors (GPCRs), the largest family of cell-
surface receptors has been known to play a critical role in the
neoplastic transformation of many cancers including hormone-
refractory cancers of breast and prostate. Some of the key func-
tions of GPCRs include regulation of cellular motility, growth and
differentiation, which play an important role in understanding the
biology of cancer (Spiegelberg and Hamm, 2007). In 1986, the
discovery of the MAS oncogene, which encodes a typical GPCR,
established a direct connection between neoplastic transformation
and GPCRs (Young et al., 1986). Many independent studies have
shown that GPCRs are over-expressed in variety of cancer types,
and contribute in cell proliferation when activated by their re-
spective circulating or locally available ligands (Even-Ram et al.,
1998; Rhodes et al., 2009). Furthermore, wild-type GPCRs could
also become oncogenic when exposed to an excess of locally
produced or circulating agonists such as gastrin-releasing peptide
(GRP), endothelin, bradykinin and Ang II (Gutkind et al., 1991;
Julius et al., 1989); in addition mutations in the conserved domain
of the GPCRs could also trigger oncogenic transformation (Allen
et al., 1991). Moreover, the activation of endothelin receptors,
bradykinin receptors, the Angiotensin II type I receptors (AGTR1)
(de Gasparo et al., 2000; Rhodes et al., 2009) and gastrin-releasingr B.V. This is an open access articlepeptide receptors (GRPR) has been implicated in prostate cancer
pathogenesis (Daaka, 2004).2. G-protein coupled receptors in breast cancer
The role of GPCRs in breast cancer (BCa) has been explored
extensively, for example protease-activated receptor 1 (PAR1) is
over-expressed in BCa and is responsible for development of me-
tastases in BCa patients (Hernandez et al., 2009). PAR1 is also
known to promote growth and invasion by promoting detachment
and migration of the epithelial cancer cells, which is a key step in
tumour metastases (Boire et al., 2005; Hernandez et al., 2009).
PAR1 also couples to multiple G-proteins (Gq/11, Gi/o, G12/13) and
activates Rho signalling (McCoy et al., 2012), thereby resulting in
changes in cytoskeleton structure and cell shape (Austin et al.,
2013), suggesting its critical role in BCa metastases. Another GPCR,
GPR116, plays an important role in cell adhesion and is found to be
a novel regulator of BCa metastasis. GPR116 regulates morphology
and cell motility through the Gαq-p63RhoGEF-RhoA/Rac1 path-
way. Activated Rho GTPases are known to induce many down-
stream signalling pathways such as ROCK1/2 during cancer cell
migration. Speciﬁcally, p63RhoGEF (GEFT), a guanine nucleotide
exchange factor (GEF) acts as an effector of the guanine-nucleotide
binding protein Gαq, thus linking GPCRs to the activation of the
Rho-GTPases. Knockdown of GPR116 in MDA-MB-231, a triple
negative, hormone-insensitive and metastatic breast cancer cellunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
A. Singh et al. / European Journal of Pharmacology 763 (2015) 178–183 179line results in signiﬁcant decrease in cell migration and invasion,
suggesting that GPR116 promotes BCa cell migration and invasion
via Gαq signalling and p63RhoGEF (a Gαq effector) mediated ac-
tivation of the RhoA and Rac1 (Tang et al., 2013). Taken together,
we speculate that targeting both PAR1 and GPR116 in triple ne-
gative breast cancer (TNBC) may hold great promise in targeting
these pathways and combating hormone-refractory breast cancer.
Nevertheless, orphan GPCRs represent a highly active area of
research that has already led to the identiﬁcation of many new
ligands for previously orphaned GPCRs. One such orphan GPCR is
GPR161, a class A rhodopsin family member. GPR161 was found to
be overexpressed speciﬁcally in TNBC and is also correlated with
poor prognosis. Importantly, knockdown of the GPR161 in basal
breast cancer cell lines demonstrated inhibition in cell prolifera-
tion. GPR161 forms a signalling complex with two scaffold pro-
teins, namely β-arrestin 2 and Ile Gln motif containing GTPase
Activating Protein 1 (IQGAP1). Cells overexpressing GPR161 acti-
vate mammalian target of rapamycin (mTOR) signalling thereby
decreasing IQGAP1 phosphorylation. Conversely, unpho-
sphorylated IQGAP1 binds mTOR which leads to the activation of
downstream signals, one of which is phosphorylation of S6, a ri-
bosomal protein (Feigin et al., 2014). Taken together, we anticipate
that tumour-speciﬁc gene expression and proteome proﬁles of the
tumour tissues and premalignant lesions, in combination with
‘reverse pharmacology’ techniques, will aid in identifying and
targeting new orphan GPCRs that may contribute to cancer in-
itiation, progression and metastases.
Another interesting member of the seven-transmembrane-
spanning G-protein coupled receptor superfamily is AGTR1, which
was prioritized as second ranked meta-outlier by employing a
bioinformatics tool named meta-Cancer Outlier Proﬁle Analysis
(MetaCOPA) using multiple independent breast cancer proﬁling
studies (Rhodes et al., 2009). As anticipated, HER2/neu was iden-
tiﬁed as the most signiﬁcant meta-outlier and AGTR1 as the sec-
ond most consistently high-scoring gene in BCa, which is also
known for its role in Ang II‐dependent vasoconstriction (Luft,
2001; Schmieder et al., 2007). While AGTR1 is found in a variety of
normal tissues, increased expression is often observed in the
corresponding neoplastic tissues, suggesting that it’s over-ex-
pression is involved in carcinogenesis (Marsigliante et al., 1996;
Takeda and Kondo, 2001). AGTR1 has also been linked to pan-
creatic, renal and ovarian cancers (Fujimoto et al., 2001; Miyajima
et al., 2002; Rivera et al., 2001; Suganuma et al., 2005; Timmer-
mans, 1999; Uemura et al., 2003) and cancer-related signalling
pathways (Amaya et al., 2004; Muscella et al., 2003). AGTR1 is
over-expressed in oestrogen receptor positive (ERþ) tumours and
mutually exclusive with HER2/neu, indicating the possibility that
over-expression of these two genes may represent alternative
pathways in breast cancer pathogenesis (Ateeq et al., 2009;
Rhodes et al., 2009). Most importantly, AGTR1 mediated oncogenic
effects could be antagonized by commonly prescribed anti-
hypertensive agents, such as losartan (Rhodes et al., 2009; Tim-
mermans, 1999). It is interesting to note that the BCa prevalence
was reported low in hypertensive patients who received angio-
tensin converting enzyme inhibitors (ACEi) previously, which
blocks the conversion of Ang I to Ang II, thereby reducing activa-
tion of AGTR1 by Ang II (Lever et al., 1998). Similarly, ARBs have
been reported to inhibit cell proliferation and angiogenesis in
prostate cancer cells (Uemura et al., 2003). Ang II mediates its
complex physiological effects by binding to two pharmacologically
distinct receptors; AGTR1 and Angiotensin II Type 2 Receptor
(AGTR2) (Timmermans et al., 1992). The stimulatory actions of Ang
II on angiogenesis, cell growth, and cell proliferation in tissues are
mediated via AGTR1 (De Paepe et al., 2001; Egami et al., 2003) and
opposed via AGTR2 (Goto et al., 2002; Silvestre et al., 2002).
Moreover, Ang II activates AGTR1, which couples to theheterotrimeric G proteins Gq/11 (to stimulate phospholipase C
mediated calcium mobilization), Gi/o, G12/13 and Gs, as well as the
other monomeric G proteins (de Gasparo et al., 2000). It has been
shown that Arhgef1, a RhoA guanine exchange factor is speciﬁcally
responsible for Ang II-induced activation of RhoA signalling and as
a result Jak2 phosphorylates Tyr738 of Arhgef1 (Guilluy et al.,
2010). In addition, activated AGTR1 also activates soluble and re-
ceptor tyrosine kinases, the mitogen-activated protein kinases
(MAPK pathway), the JAK–STAT pathway, the generation of re-
active oxygen species and various ion channels (de Gasparo et al.,
2000; Hunyady and Catt, 2006; Mehta and Griendling, 2007). Ta-
ken together, AngII–AGTR1 signalling pathways play a critical role
in the pathogenesis of AGTR1-positive breast and prostate cancer.3. Single nucleotide polymorphisms in AngII–AGTR1 pathway
Recent genome-wide association studies have revolutionized
the ﬁeld of cancer research and led to the identiﬁcation of nu-
merous single nucleotide polymorphism (SNP), which are asso-
ciated with increased risk for breast cancer (Easton et al., 2007).
For example, germline mutations in BRCA1 and BRCA2 could pre-
dispose women to BCa, as well as to ovarian cancer (King et al.,
2003). Somatic mutations in other genes, such as p53, PTEN, or
CHEK2, are also associated with increased risk of BCa (Hirshﬁeld
et al., 2010; Weischer et al., 2008). Moreover, an association be-
tween the genetic polymorphisms in the 5′ region of AGTR1 and
the increased risk of BCa has been reported among Chinese wo-
men. This study also revealed three genetic polymorphisms
A168G, C535T, T825A in the 5′ region of AGTR1. Individuals har-
bouring genotypes with one or two copies of these allelic variants
were found to be associated with 30% lower risk of BCa as com-
pared to the homozygotes (Koh et al., 2005). Conversely, another
independent study showed no signiﬁcant association between
A168G polymorphism of AGTR1 and BCa risk, but demonstrated
the signiﬁcance of AGTR2 SNPs (T1247G and A5235G) as a pre-
dictor of BCa in Brazilian women (Molina Wolgien Mdel et al.,
2014). Nevertheless, deletion of the 5′ ﬂanking region of AGTR1
showed 20-fold increase in chloramphenicol acetyltransferase re-
porter activity, thus conﬁrming the presence of a negative reg-
ulatory element(s) in the upstream region of AGTR1 (Takayanagi
et al., 1994). These observations indicate that the genetic variants
in the 5′ ﬂaking region of AGTR1 might be associated with an in-
crease in breast cancer risk. Furthermore, increased frequency of a
SNP at 1166 position (A/C transversion) in the 3′ UTR of AGTR1 has
been associated with hypertension (Bonnardeaux et al., 1994),
cardiac hypertrophy (Osterop et al., 1998), myocardial infarction
(Tiret et al., 1994) and increased oxidative stress levels in human
heart failure (Cameron et al., 2006).
An association between Angiotensin I converting enzyme
(ACE), which converts Ang I into a physiologically active form Ang
II and BCa risk has been demonstrated (Lever et al., 1998). The SNP
of ACE (A240T and I/D) regulates its level in the plasma, for ex-
ample homozygotic individuals for D or T alleles have higher ACE
levels than in the homozygotic individuals for I or A alleles.
Therefore, the individuals with ACE genotype (II or AA) have a
lower risk for BCa in comparison to the ones with high activity (DD
or TT) alleles (Koh et al., 2003, 2005). Furthermore, a SNP (A1166C)
in the AGTR1 has been associated with higher tumour node me-
tastases (TNM) stage of the BCa as compared to the individuals
harbouring A1166A (Namazi et al., 2010). However, in a follow-up
study, no association between this polymorphism and three years
disease free survival was found (Namazi et al., 2013). Conversely,
reduced plasma levels of the ACE were not always observed in the
individuals with I or A allele (Freitas-Silva et al., 2004; Haiman
et al., 2003), suggesting that the association of ACE genotype with
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that the genetic polymorphisms in AngII–AGTR1 pathway may
have racial disparity. Therefore, additional studies exploring SNPs
in the AngII–AGTR1 pathways are warranted on the populations of
different ethnicities. Moreover, a population speciﬁc genetic pro-
ﬁle could be created for evaluating cancer survival based on
prognosis markers, which would eventually help in understanding
the differences reported for the BCa incidence and outcomes,
based on geography and ethnicity.4. AngII–AGTR1 signalling mediated epithelial-to-mesenchy-
mal transition
Various cellular responses such as cell proliferation, differ-
entiation or dedifferentiation are triggered by a variety of external
stimuli, which involves the transcriptional regulation in cancer
cells through intracellular signalling cascades, including multitude
of signalling pathways that activate kinases of the mitogen-acti-
vated protein kinase (MAPK) family (Treisman, 1996) either
through receptor tyrosine kinase (RTK)- or through GPCR-trig-
gered signals (Faure et al., 1994; Pages et al., 1993; van Biesen et al.,
1996). It has been known that AGTR1 hijacks epidermal growth
factor receptor (EGFR) signalling machinery, which is critical for
the AGTR1 mediated downstream signalling and phenotypic ef-
fects, such as cellular hypertrophy and proliferation (Asakura et al.,
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Fig. 1. Major AGTR1 signalling pathways linked to cancer cell proliferation, angiogenes
losome, which activates NFκB downstream signalling. CARMA3 protein might act as a
complex. Wherein MALT1 plays a key role in stimulating IKK activity by K63 linked poly
cell proliferation, survival and migration. AngII activation of AGTR1 also leads to EGFR tr
the adaptor proteins GRB2 and SHC, resulting in prolonged EGFR–ERK signalling. Conti
phenotypic change from epithelial-to-mesenchymal transition (EMT).platelet derived growth factor receptor β (PDGFR-β) and thrombin
stimulated insulin-like growth factor-1 receptor (IGF-1R) tyrosine
phosphorylation have been reported in primary rat smooth muscle
cells (Linseman et al., 1995; Rao et al., 1995), suggesting that
transactivation of distinct RTKs might contribute in a cell-type
speciﬁc manner to GPCR mediated mitogenic signalling. Moreover,
Ang II-activated EGFR signalling in renal proximal tubule epithelial
cells results mostly by the non-ligand-mediated receptor trans-
activation mediated by ROS-dependant Src activation, which leads
to phosphorylation of both EGFR and Caveolin-1 and their asso-
ciation in the lipid rafts (Fig. 1) (Chen et al., 2012; George et al.,
2013). Thus, the constant activation of the EGFR serves as a scaf-
fold for SHC/GRB2-mediated ERK activation, subsequently result-
ing in the dedifferentiation or epithelial-to-mesenchymal transi-
tion (EMT) of renal proximal tubule epithelial cells (Chen et al.,
2012). These studies indicate that AngII–AGTR1 prolonged sig-
nalling activity in the AGTR1-positive cancers may lead to altera-
tions in gene expression and consequently elicit a phenotypic
change to EMT, which promotes aggressive phenotype and distant
metastases. Interestingly, using functional siRNA screen of the
human kinome, new signalling targets such as TRIO, BMX or CHKA
have been revealed, which upon knockdown attenuate tyrosine
phosphorylation of the EGFR by Ang II stimulation, but failed to
directly stimulate EGFR via EGF, suggesting that these proteins are
involved in AGTR1–EGFR transactivation (George et al., 2013).
Nevertheless, a deeper and comprehensive understanding of An-












is and EMT. AngII activated AGTR1 recruits a CARMA3-Bcl10-MALT1 (CBM) signa-
scaffold in recruiting Bcl 10, MALT 1 and IKKγ, the regulatory subunit of the IKK
ubiquitination utilizing IKKγ as a substrate. The activation of this pathway leads to
ansactivation via ROS‐ dependent Src kinase activation, phosphorylating EGFR and
nuous Ang II stimulation may direct alterations in the gene expression and induce
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development of novel drug targets against these pathways as an
alternative to existing cancer therapies.5. Targeting AGTR1 for enhanced drug delivery and improved
chemotherapy
Several FDA-approved ARBs, which are orally active have been
synthesized and are widely prescribed for the treatment of hy-
pertension, such as losartan, irbesartan, olmesartan, candesartan,
valsartan and telmisartan. Previously, we have shown that ectopic
over-expression of AGTR1 in immortalized normal breast epithe-
lial cells, confers an invasive phenotype upon AngII stimulation,
which was attenuated by losartan (Rhodes et al., 2009). Losartan
has also been shown to inhibit many growth factors, including
vascular endothelial growth factor (VEGF) (Arrieta et al., 2005).
Interestingly, preclinical mice experiments with control or AGTR1
overexpressing breast cancer xenografts showed differential sen-
sitivity to losartan treatment, resulting in 30% decrease in tumour
growth in AGTR1 overexpressing group, whereas no effect was
observed in the control group (Rhodes et al., 2009). Another ARB,
candesartan has been reported to reduce lung metastases, vascu-
larization and tumour growth in sarcomas and melanoma xeno-
grafts (Fujita et al., 2002; Egami et al., 2003). On the other hand,
telmisartan which is a structurally unique ARB, renders more ef-
fective inhibition of the AGTR1 mediated pro-tumorigenic effects
and the unique structural characteristics provide partial agonistic
response for a member of nuclear receptor family peroxisome
proliferator-activated receptor-γ (PPARγ) (Benson et al., 2004).
Losartan and telmisartan, both demonstrate higher tissue pene-
tration as compared to candesartan (Michel et al., 2013), which
could be a possible reason for selecting Losartan over other ARBs
for a pancreatic cancer clinical trial study (Chauhan et al., 2013).
AGTR1 employs the CARMA3-Bcl10-MALT1 (CBM) signalosome
for the activation of NF-κB signalling in endothelial and vascular
smooth muscle cells (VSMC), thus inducing pro-inﬂammatory
signalling in the vasculature that may lead to atherosclerosis
(McAllister-Lucas et al., 2010). Interestingly, Bcl10 deﬁcient mice
failed to develop Ang II‐dependent atherosclerotic lesions and
abdominal aortic aneurisms (McAllister-Lucas et al., 2010). The
decreased rate of arthrosclerosis has also been associated with
decrease in the expression of NF-κB responsive genes (Surmi and
Hasty, 2010). Interestingly, siRNA mediated knockdown of CAR-
MA3 in AGTR1 over-expressing immortalized VSMC cell lines,
showed no response to Ang II dependent ERK activation or TNFα‐
dependent pIκB generation (McAllister-Lucas et al., 2010), sug-
gesting that CARMA3 protein might act as a scaffold in recruiting
Bcl10, MALT1 and IKKγ, the regulatory subunit of the IKK complex
(Stilo et al., 2004). These observations gain much more importance
in light of the recent discovery of an inhibitor of MALT1 protease, a
component of the signalosome that is enzymatically active and
communicates downstream with NF-κB signalling (Rebeaud et al.,
2008). Hence we can infer that the CBM signalosome may play a
major role in AGTR1 mediated breast cancer pathogenesis, and
MALT1 or Bcl10 inhibitors might prove as promising targets.
On another note, proliferating cancer cells are known to con-
secutively create a new solid substance comprising cells and ma-
trix components, which generate radial and circumferential solid
stress (Kharaishvili et al., 2014). This stress in the growing tumour
collapses blood vessels and limits perfusion resulting in extensive
hypoxia and impaired drug delivery (Griffon-Etienne et al., 1999;
Janmey and McCulloch, 2007; Padera et al., 2004). As a result,
cancer patients with low tumour perfusion show poor che-
motherapy responses and shorter survival versus patients with
high perfusion (Park et al., 2009; Sorensen et al., 2011).Interestingly, AGTR1 inhibitors/antagonists have been known to
increase vessel perfusion through vascular decompression, there-
by reducing stromal activity and production of matrix components
responsible for compression. Likewise, AGTR2 agonists or in-
hibitors of downstream signalling through TGF-β1, CCN2 or ET-1
have been known in reducing solid stress to enhance che-
motherapy and overcome challenges associated with che-
motherapies (Chauhan et al., 2013). Furthermore, AGTR1 signalling
plays an important role in increasing VEGF expression by Cancer
Associated Fibroblasts (CAFs) (Fujita et al., 2005), thus both ACE
and AGTR1 inhibitors could be used to target VEGF expression and
angiogenesis (Suganuma et al., 2005; Yoshiji et al., 2001).
ACE inhibitors (ACEi), which have been successfully used as
antihypertensive drugs for the past 20 years, are now being in-
vestigated for their possible role as anticancer compounds (Lind-
berg et al., 2004). Interestingly, epidemiological study suggests
that the long-term treatment of ACEi such as captopril, lisinopril
and enalapril has reduced the incidence of lung and breast cancer
(Lever et al., 1998). However, other epidemiological studies were
not in concordance with these results and showed that ACEi
treatment had no signiﬁcant effect on cancer (Friis et al., 2001; Li
et al., 2003; Lindholm et al., 2001). One possible explanation might
be that the latter studies enroled older patients who underwent
treatment for shorter duration. Moreover, use of different ACEi on
diverse population of patients along with variability in the dosage,
duration of drug prescription as well as patient compliance might
be the possible reasons for the contradictory results (Deshayes and
Nahmias, 2005). Taken together, ACE and AGTR1 blockers could be
used as an adjuvant therapy along with established chemother-
apeutic drugs to further potentiate the anti-cancer effects of the
conventional cancer therapies. Speciﬁcally, AngII–AGTR1 axis
could be further explored as a potential therapeutic target for
treating AGTR1 positive cancers including AGTR1 and ER-positive
BCa. However, in light of the observation of ACE and AGTR1
polymorphisms, more population speciﬁc studies need to be car-
ried out to fully understand the role of ACEi and ARBs with respect
to anticancer therapy, with an ultimate goal of designing the fra-
mework for clinical trials and developing tailored treatment plan
for cancer patients.Acknowledgements
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